Mylan Can't Get Top Court Review Of $76M Antitrust Ruling

Law360, New York (October 3, 2011, 3:10 PM EDT) -- The U.S. Supreme Court on Monday declined to hear Mylan Laboratories Inc.'s appeal of a $76 million antitrust verdict over licensing agreements for anti-anxiety medications based on Mylan's claims that the insurance company plaintiffs could not establish subject matter jurisdiction.

The high court denied Mylan's petition for certiorari, which claimed that the insurance companies that brought the case against it could not show diversity of citizenship, asking the court to decide whether diversity jurisdiction can be created retroactively after a trial in which the plaintiffs' residency...
To view the full article, register now.